Nuclera Launches Nanodisc Panel for GPCR Proteins

New biotech tool aims to streamline membrane protein production.

Mar. 30, 2026 at 6:09pm

Got story updates? Submit your updates here. ›

An abstract, textured painting featuring bold geometric shapes, sweeping arcs, and precise botanical spirals in earthy tones, conceptually representing the complex structure and interactions of G-protein coupled receptors.Nuclera's new nanodisc platform aims to streamline the study of G-protein coupled receptors, a large family of cell surface proteins that are crucial drug targets.Boston Today

Nuclera, a biotechnology company focused on enabling rapid access to high-quality proteins, has announced the launch of its new nanodisc panel designed specifically for G-protein coupled receptor (GPCR) proteins. The panel is intended to help streamline the production and study of these important membrane proteins.

Why it matters

GPCRs are a large family of cell surface receptors that play crucial roles in many biological processes and are targets for a significant portion of modern pharmaceuticals. However, the production and purification of these membrane-bound proteins can be technically challenging. Nuclera's new nanodisc panel aims to simplify this process and accelerate GPCR research and drug discovery.

The details

Nuclera's nanodisc panel provides a platform for expressing, purifying, and stabilizing GPCRs in a native-like lipid environment. Nanodiscs are small discoidal lipid bilayers that can incorporate membrane proteins, allowing them to be studied outside of a cell membrane. The company says this new panel will enable researchers to more easily produce high-quality GPCR samples for structural studies, functional assays, and other applications.

  • Nuclera announced the launch of the new nanodisc panel on March 30, 2026.

The players

Nuclera

A biotechnology company focused on enabling rapid access to high-quality proteins.

Got photos? Submit your photos here. ›

What’s next

The new nanodisc panel is now available for purchase by researchers studying GPCRs and other membrane proteins.

The takeaway

Nuclera's latest innovation aims to simplify the production of GPCR proteins, which are important drug targets but notoriously difficult to work with. This new tool could accelerate structural studies and drug discovery efforts focused on this large family of cell surface receptors.